Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$341.0m

Jasper Therapeutics Management

Management criteria checks 2/4

Jasper Therapeutics' CEO is Ron Martell, appointed in Mar 2022, has a tenure of 2.67 years. total yearly compensation is $3.37M, comprised of 20.6% salary and 79.4% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $752.78K. The average tenure of the management team and the board of directors is 2.3 years and 2.2 years respectively.

Key information

Ron Martell

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage20.6%
CEO tenure2.7yrs
CEO ownership0.2%
Management average tenure2.3yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Ron Martell's remuneration changed compared to Jasper Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$62m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$3mUS$695k

-US$64m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$6mUS$510k

-US$38m

Compensation vs Market: Ron's total compensation ($USD3.37M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.

CEO

Ron Martell (62 yo)

2.7yrs

Tenure

US$3,369,990

Compensation

Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics, Inc. since March 15, 2022. He has been Chief Financial Officer and Director at Morp...

Leadership Team

NamePositionTenureCompensationOwnership
Ronald Martell
President2.7yrsUS$3.37m0.22%
$ 752.8k
Judith Shizuru
Co-Founder & Directorno dataUS$357.71k0.77%
$ 2.6m
Jeetinder Mahal
Chief Operating Officer2.7yrsUS$1.18m0.17%
$ 568.4k
Edwin Tucker
Chief Medical Officer1.4yrsUS$977.73k0.0027%
$ 9.1k
Herbert Cross
CFO & Corporate Secretary1.2yrsno datano data
Luca Di Noto
Senior Vice President of Technical Operations4.8yrsno datano data
David Ku
Vice President of Corporate Developmentno datano datano data
Matthew Ford
Vice President of Human Resources1.8yrsno datano data
Wendy Pang
Senior Vice President of Research & Translational Medicine2.7yrsno datano data
Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality1.3yrsno datano data

2.3yrs

Average Tenure

52yo

Average Age

Experienced Management: JSPR's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ronald Martell
President2.7yrsUS$3.37m0.22%
$ 752.8k
Judith Shizuru
Co-Founder & Director6.7yrsUS$357.71k0.77%
$ 2.6m
Thomas Wiggans
Independent Chairmanless than a yearUS$76.47k0.033%
$ 113.6k
Kurt von Emster
Independent Director5yrsUS$128.21k0.014%
$ 48.1k
Daniel Adelman
Member of Scientific Advisory Board & Senior Clinical Advisor1.4yrsno datano data
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Frederick Appelbaum
Member of Scientific Advisory Boardno datano datano data
Jeffrey Ravetch
Member of Scientific Advisory Boardno datano datano data
Stephen Galli
Member of Scientific Advisory Board1.5yrsno datano data
Vishal Kapoor
Independent Director1.8yrsUS$266.47k0.029%
$ 99.4k
Harry Malech
Member of Scientific Advisory Boardno datano datano data
Christian Nolet
Independent Director3.2yrsUS$126.41k0.022%
$ 73.9k

2.2yrs

Average Tenure

67yo

Average Age

Experienced Board: JSPR's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.